Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European Countries

References

• Staskin D, Herschorn S, Fialkov J, LM T, Walsh T, Schermer CR. A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study). Int Urogynecol J. 2018;29(2):273–283. doi:10.1007/s00192-017-3377-528620791
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Navarro-Artieda R, Ruiz-Torrejon A, Saez M, Coll-de Tuero G, Sanchez L. [A retrospective, observational and multicentre study on patients with hyperactive bladder on treatment with mirabegron and oxybutinine under usual clinical practice conditions]. Semergen. 2017;43(4):277–288. doi:10.1016/j.semerg.2016.05.00627371430
   PubMedGoogle Scholar
• Meves SH, Hummel T, Endres HG, et al. Effectiveness of antiplatelet therapy in atherosclerotic disease: comparing the ASA low-response prevalence in CVD, CAD and PAD. J Thromb Thrombolysis. 2014;37(2):190–201. doi:10.1007/s11239-013-0919-723553246
   PubMed Web of Science ®Google Scholar
• Guideline on Good Pharmacovigilance Practices (GVP) - Module IX – Signal Management (Rev 1). Vol. 2017 European Medicines Agency and Heads of Medicines Agencies; 2017.
   Google Scholar
• Drug utilization study of mirabegron (Betmiga®) using real-world healthcare databases from the Netherlands. EU PAS Register Number 15063. Spain, UK and Finland 2017 Available from: http://www.encepp.eu/encepp/viewResource.htm?id=29595. Accessed 313, 2020.
   Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index. Available from: https://www.whocc.no/atc_ddd_index/. Accessed 313, 2020 2019.
   Google Scholar
• Catalan V, Lelorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health. 2000;3(6):417–426. doi:10.1046/j.1524-4733.2000.36006.x16464201
   PubMedGoogle Scholar
• Thomsen TL, Heintjes EM, Penning-van Beest FJA, Christensen TE, Herings RMC. Fewer treatment changes with premixed insulin analogues compared to premixed human insulin – a real-life treatment pattern analysis of patients with type 2 diabetes in the Netherlands. Value Health. 132010.
   Google Scholar
• Heintjes EM, Thomsen TL, Penning-van Beest FJA, Christensen TE, Herings RMC. Glycaemic control and insulin utilisation in patients with type 2 diabetes initiated on a long-acting insulin analogue in a Dutch real-life setting. Value Health. 2010;132010:A55.
   Web of Science ®Google Scholar
• Bartelink ME, Elsman BH, Oostindjer Aet al,. NHG-Standaard Cardiovascular risicomanagement(Tweede herziening). Huisarts Wet. 2012;55(1):15.
   Google Scholar
• Agency EM. Summary of Product Characteristics Betmiga; 2012.
   Google Scholar
• Kontopantelis E, Doran T, Springate DA, Buchan I, Reeves D. Regression based quasi-experimental approach when randomisation is not an option: interrupted time series analysis. BMJ. 2015;350:h2750. doi:10.1136/bmj.h275026058820
   PubMed Web of Science ®Google Scholar
• Hawley S, Leal J, Delmestri A, et al. Anti-osteoporosis medication prescriptions and incidence of subsequent fracture among primary hip fracture patients in England and Wales: an interrupted time-series analysis. J Bone Miner Res. 2016;31(11):2008–2015. doi:10.1002/jbmr.v31.1127377877
   PubMed Web of Science ®Google Scholar
• Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299–309. doi:10.1046/j.1365-2710.2002.00430.x12174032
   PubMed Web of Science ®Google Scholar
• Zhang F, Wagner AK, Soumerai SB, Ross-Degnan D. Methods for estimating confidence intervals in interrupted time series analyses of health interventions. J Clin Epidemiol. 2009;62(2):143–148. doi:10.1016/j.jclinepi.2008.08.00719010644
   PubMed Web of Science ®Google Scholar
• Hawley S, MS A, Berencsi K, Judge A, Prieto-Alhambra D. Sample size and power considerations for ordinary least squares interrupted time series analysis: a simulation study. Clin Epidemiol. 2019;11(197–205):197–205. doi:10.2147/CLEP30881136
   PubMed Web of Science ®Google Scholar
• Kilpelainen K, Tuomi-Nikula A, Thelen J, et al. Health indicators in Europe: availability and data needs. Eur J Public Health. 2012;22(5):716–721. doi:10.1093/eurpub/ckr19522294775
   PubMed Web of Science ®Google Scholar
• Marston L, Carpenter JR, Walters KR, Morris RW, Nazareth I, Petersen I. Issues in multiple imputation of missing data for large general practice clinical databases. Pharmacoepidemiol Drug Saf. 2010;19(6):618–626. doi:10.1002/pds.v19:620306452
   PubMed Web of Science ®Google Scholar
• Phelan M, Bhavsar NA, Goldstein BA. Illustrating informed presence bias in electronic health records data: how patient interactions with a health system can impact inference. EGEMS (Washington, DC). 2017;5(1):22.
   Google Scholar
• Stevens SL, McManus RJ, Stevens RJ. Current practice of usual clinic blood pressure measurement in people with and without diabetes: a survey and prospective ‘mystery shopper’ study in UK primary care. BMJ Open. 2018;8(4):e020589. doi:10.1136/bmjopen-2017-020589
   Web of Science ®Google Scholar
• Luymes CH, de Ruijter W, Poortvliet RK, et al. Change in calculated cardiovascular risk due to guideline revision: a cross-sectional study in the Netherlands. Eur J Gen Pract. 2015;21(4):217–223. doi:10.3109/13814788.2015.106438926230039
   PubMed Web of Science ®Google Scholar
• Rosell-Murphy M, Rodriguez-Blanco T, Moran J, et al. Variability in screening prevention activities in primary care in Spain: a multilevel analysis. BMC Public Health. 2015;15(1):473. doi:10.1186/s12889-015-1767-525947302
   PubMed Web of Science ®Google Scholar
• Peng M, Chen G, Kaplan GG, et al. Methods of defining hypertension in electronic medical records: validation against national survey data. J Public Health (Oxf). 2016;38(3):e392–e399. doi:10.1093/pubmed/fdv15526547088
   PubMed Web of Science ®Google Scholar
• Suija K, Kivisto K, Sarria-Santamera A, et al. Challenges of audit of care on clinical quality indicators for hypertension and type 2 diabetes across four European countries. Fam Pract. 2015;32(1):69–74. doi:10.1093/fampra/cmu07825411423
   PubMed Web of Science ®Google Scholar
• NICE Quality and Outcomes Framework indicator. The National Institute for Health and Care Excellence (NICE). Available from: https://www.nice.org.uk/standards-and-indicators/qofindicators?categories=&page=3. Accessed 283 2019,2019.
   Google Scholar
• Sidorenkov G, Voorham J, de Zeeuw D, Haaijer-Ruskamp FM, Denig P. Do treatment quality indicators predict cardiovascular outcomes in patients with diabetes? PLoS One. 2013;8(10):e78821. doi:10.1371/journal.pone.007882124205325
   PubMed Web of Science ®Google Scholar
• Wilson A. Building primary care in a changing Europe: case studies [Internet]. 2015(Observatory Studies Series, No. 40.). UK Available from: https://www.ncbi.nlm.nih.gov/books/NBK459014/. Accessed 313, 2020.
   Google Scholar
• Dedeu T, Bolibar B, Gené J, Pareja C, Violan C. Building primary care in a changing Europe: case studies [Internet]. 2015(Observatory Studies Series, No. 40.). Spain Available from: https://www.ncbi.nlm.nih.gov/books/NBK459029/. Accessed 313, 2020.
   Google Scholar
• Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open. 2018;8(11):e021889. doi:10.1136/bmjopen-2018-021889
   PubMed Web of Science ®Google Scholar
• Margulis AV, Linder M, Arana A, et al. Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom. PLoS One. 2018;13(9):e0204456. doi:10.1371/journal.pone.020445630260993
   PubMed Web of Science ®Google Scholar